PACKAGE INSERT. Each tablet contains the following active ingredients: 500 mg paracetamol,

Size: px
Start display at page:

Download "PACKAGE INSERT. Each tablet contains the following active ingredients: 500 mg paracetamol,"

Transcription

1 . PACKAGE INSERT SCHEDULING STATUS Schedule 2 PROPRIETARY NAME AND DOSAGE FORM SINUMAX WITH CODEINE tablets COMPOSITION Each tablet contains the following active ingredients: 500 mg paracetamol, 30 mg pseudoephedrine hydrochloride and 8 mg codeine phosphate. Inactive ingredients: magnesium stearate, pregelatinised starch, sodium starch glycolate, microcrystalline cellulose (Avicel). PHARMACOLOGICAL CLASSIFICATION A. 5.8 Preparations for the common cold including nasal decongestants and antihistaminics. PHARMACOLOGICAL ACTION SINUMAX WITH CODEINE contains paracetamol, pseudoephedrine hydrochloride and codeine phosphate. Paracetamol has analgesic and antipyretic effects. Pseudoephedrine relieves nasal congestion. Codeine phosphate has analgesic effects. INDICATIONS For the symptomatic relief of nasal, sinus and Eustachian tube mucal congestion in the presence of mild to moderate pain and fever due to colds and influenza. CONTRAINDICATIONS Page 1 of 23

2 Do not use this product if you are allergic to any of the ingredients. This product should not be used by patients being treated with monoamine oxidase inhibitors, or within two weeks of stopping treatment with these medications. Paracetamol should not be used in patients with severe liver disease. Pseudoephedrine should not be used in patients suffering from any of the following: heart disease (especially coronary insufficiency or arrhythmias), high blood pressure (hypertension), an overactive thyroid gland (hyperthyroidism), tumour of the adrenal gland (phaeochromocytoma) and raised intraocular pressure (closed-angle glaucoma). Pseudoephedrine should be avoided in patients receiving chloroform, cyclopropane, halothane or other halogenated anaesthetics. Codeine should not be used during an attack of bronchial asthma or in patients with heart failure as a result of lung disease and should be avoided by patients with abnormally slow and/or shallow breathing, especially in the presence of blueish discolouration of skin due to lack of oxygen and excessive bronchial secretion and after operations on the biliary tract; in the presence of acute alcoholism, head injuries and conditions in which the pressure inside the skull is raised. WARNINGS AND SPECIAL PRECAUTIONS Page 2 of 23

3 Paracetamol This product contains paracetamol which may be fatal in overdose. In the event of overdosage or suspected overdose and notwithstanding the fact that the person may be asymptomatic, the nearest doctor, hospital or Poison Centre must be contacted immediately. Taking more than the recommended dose may cause severe liver damage. Patients suffering from liver or kidney disease should take paracetamol only if instructed to do so by the doctor. Consult your doctor if no relief is obtained with the recommended dosage. Do not use continuously for longer than 5 days without consulting your doctor. Exceeding the prescribed dose, together with prolonged and continuous use of this medication may lead to dependency and addiction. Rapid Metabolisers of Codeine Some individuals may be rapid metabolisers due to a specific CYP2D6*2x2 genotype. These individuals convert codeine into the active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at the recommended dosage regimen for SINUMAX WITH CODEINE, individuals who are rapid metabolisers may experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. The prevalence of this CYP2D6 phenotype may vary between ethnic groups. Page 3 of 23

4 Patients should take the lowest effective dose for the shortest period of time. Patients should be informed about these risks and the signs of morphine overdose (see Pregnancy and Lactation). Special Precautions Pseudoepehdrine Tolerance with dependence may occur after continued use. The effects of pseudoephedrine are lessened by medicines containing guanethidine, reserpine, methyldopa and may be diminished or enhanced by tricyclic antidepressants. It may increase the possibility of irregular heart beat in patients taking digitalis. Codeine Codeine should be given with caution to patients with an underactive thyroid or adrenal gland (hypothyroidism, adrenal insufficiency), myasthenia gravis or impaired kidney or liver function, enlargement of prostate gland (prostatic hypertrophy) or shock. It should be used with care in patients with inflamed or obstructive bowel disease. The dosage should be reduced in elderly patients. The depressant effects of codeine are enhanced by agents which slow down the action of the central nervous system such as alcohol, anaesthetics, hypnotics and sedatives, phenothiazines, and tricyclic antidepressants. Prolonged use of high doses of codeine has produced addiction of the morphine type. Codeine may cause abnormally slow and/or shallow breathing in the newborn infant if given during labour. Effects on Ability to Drive or Use Machines Exercise caution when driving a motor vehicle or operating machinery. Page 4 of 23

5 INTERACTIONS Alcohol and drugs that induce liver enzymes can increase the hepatotoxicity of paracetamol. PREGNANCY AND LACTION Do not take this product during pregnancy or whilst breastfeeding. Codeine and its active metabolite, morphine, are secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low. Some women rapidly metabolise codeine, which may result in higher serum levels of codeine s active metabolite, morphine, in breast milk and, therefore, potentially dangerous levels of serum morphine in their breastfed infants. This could lead to potentially serious adverse reactions, including death, in nursing infants. Mothers using codeine should be informed about how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. Breastfeeding mothers should be instructed to talk to the baby s doctor immediately or seek emergency medical care. Breastfeeding mothers who rapidly metabolise codeine may also experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. Prescribers should closely monitor motherinfant pairs and notify treating paediatricians about the use of codeine during breastfeeding. DOSAGE AND DIRECTIONS FOR USE DO NOT EXCEED THE RECOMMENDED DOSE Adults (and children over 12 years): ONE to TWO tablets every four to six hours. Do not exceed eight tablets in 24 hours. Page 5 of 23

6 Children 6 to 12 years: A half to one tablet every six hours. Do not exceed four tablets in 24 hours. Do not use for longer than 5 days. Not recommended for children under 6 years. SIDE-EFFECTS The following side effects have been reported but frequencies are unknown: System organ class Adverse event Immune System Disorders Allergic reactions. Skin and Subcutaneous Tissue Disorders Dermatitis, skin rash and other allergic reactions. The rash is usually erythematous or urticarial and may be accompanied by fever and mucosal lesions. Pruritus/itching, sweating, facial flushing. Blood and lymphatic system Disorders Leukopenia, pancytopenia, neutropenia, haemolysis (in patients with glucose-6-phosphate dehydrogenase). Nervous System Disorders Headache, dizziness, somnolence, tremor, restlessness. Gastro-intestinal disorders Nausea, vomiting, constipation, dry mouth, thirst. Psychiatric disorders Insomnia, anxiety, somnolence/sleepiness, confusion, mood changes. Page 6 of 23

7 Cardiac Disorders Tachycardia, ventricular arrhythmia, precordial pain, palpitations, bradycardia, hypertension. Musculoskeletal and Muscular weakness. connective tissue Disorders Renal and urinary Disorders Difficulty in urination with kidney duct or bile duct spasm Eye Disorders Contraction of the pupil of the eye. Vascular Disorders: Postural hypotension, increased pressure inside the skull. General disorders: Fever, abnormally low body temperature. KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT If more than the recommended dose has been taken speak to your doctor or take the patient to the nearest hospital immediately. For additional emergency information, call your nearest poison centre. Paracetamol Prompt treatment is essential. In the event of an overdosage, consult a doctor immediately, or take the person to a hospital directly. A delay in starting treatment may mean that antidote is given too late to be effective. Evidence of liver damage is often delayed until after the time for effective treatment has lapsed. Page 7 of 23

8 Susceptibility to paracetamol toxicity is increased in patients who have taken repeated high doses (greater than 5-10 g/day) of paracetamol for several days, in chronic alcoholism, chronic liver disease, AIDS, malnutrition, and with the use of drugs that induce liver microsomal oxidation such as barbiturates, isoniazid, rifampicin, phenytoin and carbamazepine. Symptoms of paracetamol overdosage in the first 24 hours include pallor, nausea, vomiting, anorexia and possibly abdominal pain. Mild symptoms during the first two days of acute poisoning do not reflect the potential seriousness of the overdosage. Liver damage may become apparent 12 to 48 hours, or later after ingestion, initially by elevation of the serum transaminase and lactic dehydrogenase activity, increased serum bilirubin concentration and prolongation of the prothrombin time. Liver damage may lead to encephalopathy, coma and death. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Abnormalities of glucose metabolism and metabolic acidosis may occur. Cardiac arrhythmias have been reported. Treatment for paracetamol overdosage: Although evidence is limited it is recommended that any adult person who has ingested 5-10 grams or more of paracetamol (or a child who has had more than 140 mg/kg) within the preceding four hours, should have the stomach emptied by lavage (emesis may be adequate for children) and a single dose of 50 g activated charcoal given via the lavage tube. Ingestion of amounts of paracetamol smaller than this may require treatment in patients susceptible to paracetamol poisoning (see above). In patients who are stuperose or comatose endotracheal intubation should precede gastric lavage in order to avoid aspiration. N-acetylcysteine should be administered to all cases of suspected overdose as soon as possible preferably within eight hours of overdosage, although treatment up to 36 hours after ingestion may still Page 8 of 23

9 be of benefit, especially if more than 150 mg/kg of paracetamol was taken. An initial dose of 150 mg/kg N-acetylcysteine in 200 ml dextrose injection given intravenously over 15 minutes, followed by an infusion of 50 mg/kg in 500 ml dextrose injection over the next four hours, and then 100 mg/kg in ml dextrose injection over the next sixteen hours. The volume of intravenous fluid should be modified for children. Although the oral formulation is not the treatment of choice, 140 mg/kg dissolved in water may be administered initially, followed by 70 mg/kg every four hours for seventeen doses. A plasma paracetamol level should be determined four hours after ingestion in all cases of suspected overdosage. Levels done before four hours, unless high, may be misleading. Patients at risk of liver damage, and hence requiring continued treatment with N-acetylcysteine, can be identified according to their plasma paracetamol level. The plasma paracetamol level can be plotted against time since ingestion in the normogram below. Source: Goodman & Gilman s The Pharmacological Basis of Therapeutics, 11 th Ed. Page 9 of 23

10 Those whose plasma paracetamol levels are above the normal treatment line, should continue N-acetylcysteine treatment with 100 mg/kg IV over sixteen hours repeatedly until recovery. Patients with increased susceptibility to liver damage as identified above, should continue treatment if concentrations are above the high risk treatment line. Prothrombin index correlates best with survival. Monitor all patients with significant ingestions for at least ninety six hours. Pseudoephedrine Symptoms from pseudoephedrine overdose consist most often of mild anxiety, increased rate of heart beat and/or mild high blood pressure. Symptoms usually appear within 4 to 8 hours of being taken. Codeine Codeine overdosage may cause symptoms, which include restlessness, excitement, abnormally slow and/or shallow breathing and low blood pressure with failure of the circulatory system and coma. In children fits may occur. The specific antagonist, naloxone hydrochloride may be used to counteract severe respiratory depression. IDENTIFICATION A flat round, white tablet with bevelled edges and "SINUMAX CO" embossed on the one side and a breakline on the other side. PRESENTATION Securitainers of 20 tablets. STORAGE INSTRUCTIONS Store at or below 25 C. Protect from light, moisture and exposure to air. KEEP OUT OF REACH OF CHILDREN Page 10 of 23

11 REGISTRATION NUMBER 29/5.8/0004 NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION JANSSEN PHARMACEUTICA (Pty) Ltd (Reg no. 1980/011122/07) Building 6, Country Club Estate, 21 Woodlands Drive, Woodmead, 2191 Tel: +27 (11) DATE OF PUBLICATION OF THE PACKAGE INSERT February 2015 Page 11 of 23

12 VOUBILJET SKEDULERINGSTATUS Skedule 2 EIENDOMSNAAM EN DOSEERVORM SINUMAX WITH CODEINE tablette SAMESTELLING Elke tablet bevat die volgende aktiewe bestanddele: 500 mg parasetamol, 30 mg pseudoefedrienhidrochloried en 8 mg kodeïenfosfaat. Onaktiewe bestanddele: magnesiumstearaat, vooraf-gelatineerde stysel, natriumstyselglikolaat, mikrokristallyne sellulose (Avicel). FARMAKOLOGIESE KLASSIFIKASIE A. 5.8 Verkouemiddels, insluitende neusontstoppingsmiddels en antihistaminika. FARMAKOLOGIESE WERKING SINUMAX WITH CODEINE bevat parasetamol, pseudoefedrienhidrochloried en kodeïenfosfaat. Parasetamol het ʼn analgetiese en koorswerende effek. Pseudoefedrien verlig neuskongestie. Kodeïenfosfaat het ʼn analgetiese effek. INDIKASIES Vir die simptomatiese verligting van neus, sinus en buis van Eustachius slymverstopping in die teenwoordigheid van ligte tot matige pyn en koors weens verkoue en griep. Page 12 of 23

13 KONTRA-INDIKASIES Moenie hierdie produk gebruik indien jy allergies is vir enige van die bestanddele nie. Die produk moet nie deur pasiënte gebruik word wat tans behandel word met mono-mienoksidaseremmers, of binne twee weke na die staking van behandeling met hierdie medisyne nie. Parasetamol moet nie aan pasiënte met erge lewersiektes gegee word nie. Pseudoefedrien moet nie aan pasiënte wat aan enige van die volgende ly, gegee word nie: hartsiektes (veral koronêre ontoereikendheid of disritmieë), hoë bloeddruk (hipertensie), ʼn ooraktiewe skildklier (hipertiroïdisme), gewas van die bynier (feochromositoom) en verhoogde intra-okulêre druk (geslotehoekgloukoom). Pseudoefedrien moet vermy word by pasiënte wat narkose met chloroform, siklopropaan, halotaan of ander gehalogeneerde narkosemiddels ondergaan. Kodeïen moet nie tydens ʼn akute brongiale asma-aanval of by pasiënte met hartversaking as gevolg van longsiektes, gebruik word nie. Die gebruik moet ook vermy word by pasiënte met abnormale stadige en/of vlak asemhaling, veral in die teenwoordigheid van ʼn blouerige verkleuring van die vel as gevolg van ʼn tekort aan suurstof en oormatige brongiale afskeidings en na operasies aan die galblaas; in die teenwoordigheid van akute alkoholisme, kopbeserings en toestande waar die druk in die skedel verhoog is. Page 13 of 23

14 WAARSKUWINGS EN SPESIALE VOORSORGMAATREËLS Parasetamol Hierdie produk bevat parasetamol, wat noodlottig kan wees met oordosering. In geval van oordosering of vermoedelike oordosering en ten spyte van die feit dat die persoon moontlik asimptomaties kan wees, moet die naaste dokter, hospitaal of vergiftigingsentrum onmiddellik geskakel word. Ernstige lewerskade kan ontstaan indien die voorgeskrewe dosis oorskry word. Pasiënte wat aan lewer- of niersiektes ly behoort parasetamol slegs te gebruik indien dit deur ʼn geneesheer voorgeskryf is. Raadpleeg jou geneesheer indien geen verligting verkry word met die aanbevole dosis nie. Moenie vir langer as 5 dae ononderbroke gebruik sonder om ʼn geneesheer te raadpleeg nie. Indien die voorgeskrewe dosis oorskry word, tesame met langdurige en aanhoudende gebruik van die medisyne, kan dit tot afhanklikheid en verslawing lei. Vinnige metaboliseerders van kodeïen Sommige individue kan vinnige metaboliseerders wees as gevolg van n spesifieke CYP2D6*2x2 genotipe. Hierdie individue skakel kodeïen vinniger en meer volledig om na die aktiewe metaboliet, morfien, as ander mense. Hierdie vinnige omsetting lei tot hoër as verwagte serum-morfienvlakke. Selfs by die voorgeskrewe doseringsriglyne vir SINUMAX WITH CODEINE kan individue wat vinnige metaboliseerders is, oordoseringsimptome soos buitensporige lomerigheid, verwarring, of vlak asemhaling ondervind. Die voorkoms van hierdie CYP2D6 fenotipe kan verskil tussen etniese groepe. Page 14 of 23

15 Pasiënte moet die laagste doeltreffende dosis vir die kortste tyd te neem. Pasiënte moet ingelig word oor hierdie risiko s en die tekens van morfien-oordosering (sien Swangerskap en Laktasie). Spesiale voorsorgmaatreëls Pseudoefedrien Toleransie met afhanklikheid kan voorkom na volgehoue gebruik. Die uitwerking van pseudoefedrien word verminder deur middels wat guanetidien, reserpien of metieldopa bevat en kan verminder of versterk word deur trisikliese antidepressante Dit kan die moontlikheid vir ongereëlde hartklop vermeerder by pasiënte wat digitalis neem. Kodeïen Kodeïen behoort met versigtigheid aan pasiënte met ʼn onderaktiewe skild- of bynier (hipotiroïdisme, swak bynierfunksie), miastenie gravis of verswakte nier- of lewerfunksie, vergrote prostaatklier (prostaathipertrofie) of skok gegee te word. Dit moet met versigtigheid gebruik word by pasiënte met ontsteekte derms of obstruktiewe dermsiekte. Die dosis moet verminder word by bejaarde pasiënte. Die onderdrukkende uitwerking van kodeïen word versterk deur middels wat die sentrale senuweestelsel onderdruk, soos alkohol, narkosemiddels, slaap- en susmiddels, fenotiasiene en trisikliese antidepressante. Langdurige gebruik van hoë dosisse kodeïen het al gelei tot ʼn morfienagtige verslawing. Kodeïen kan ook aanleiding gee tot abnormale stadige en/of vlak asemhaling by pasgebore babas indien dit tydens die bevalling toegedien word. Page 15 of 23

16 Effek op die vermoë om te bestuur en masjinerie te gebruik Versigtigheid moet aan die dag gelê word indien ʼn motor bestuur word of masjinerie hanteer word. INTERAKSIES Alkohol en medisyne wat lewerensieme kan induseer kan die hepatotoksisiteit van parasetamol verhoog. SWANGERSKAP EN LAKTASIE Moenie hierdie produk tydens swangerskap en borsvoeding neem nie. Kodeïen en die aktiewe metaboliet, morfien, word in menslike melk uitgeskei. By vroue met normale kodeïenmetabolisme (normale CYP2D6 werking), is die hoeveelheid kodeïen wat in moedersmelk uitgeskei word, gering. Sommige vroue metaboliseer kodeïen vinnig, wat kan lei tot hoër serumvlakke van kodeïen se aktiewe metaboliet, morfien, in die borsmelk en dus moontlik gevaarlike vlakke van morfien in die serum van die babas wat hulle borsvoed. Dit kan tot moontlik ernstige newe-effekte lei, insluitende dood, by babas wat borsvoeding ontvang. Moeders wat kodeïen gebruik moet ingelig word hoe om die tekens en simptome van neonatale toksisiteit, soos slaperigheid en kalmering, moeilike borsvoeding, asemhalingsprobleme en verlaagde spiertonus by die pasgeborene te identifiseer. Moeders wat borsvoed moet ingelig word dat hulle onmiddellik met hulle baba se dokter moet praat of nood-mediese versorging moet bekom. Moeders wat borsvoed en wat kodeïen vinnig metaboliseer kan ook oordoseringsimptome soos buitengewone slaperigheid, verwarring, of vlak asemhaling ervaar. Voorskrif-uitreikers moet die moeder-kind paar deeglik moniteer en die verantwoordelike pediater inlig oor die gebruik van die kodeïen tydens borsvoeding. DOSIS EN GEBRUIKSAANWYSINGS Page 16 of 23

17 MOENIE DIE AANBEVOLE DOSIS OORSKRY NIE Volwassenes (en kinders ouer as 12 jaar): EEN tot TWEE tablette elke vier tot ses uur. Moenie meer as agt tablette in 24 uur neem nie. Kinders 6 tot 12 jaar: ʼn Halwe tot een tablet elke ses uur. Moenie meer as vier tablette in 24 uur neem nie. Moenie langer as 5 dae gebruik nie. Nie aanbeveel vir kinders jonger as 6 jaar nie. NEWE-EFFEKTE Die volgende newe-effekte is aangemeld maar die voorkoms is onbekend: Orgaansisteem klas Newe-effek Immuunstelsel afwykings Allergiese reaksies Vel- en subkutane weefsel afwykings Dermatitis, vel uitslag en ander allergiese reaksies. Die uitslag is gewoonlik eritemateus of urtikaries en kan gepaard gaan met koors en slymvliesletsels. Pruritus/jeuk, sweet, blosende gesig. Page 17 of 23

18 Bloed- en limfatiese sisteem afwykings Leukopenie, pansitopenie, neutropenie, hemolise (by pasiënte met glukose-6-fosfaatdehidrogenase) Sentrale senuweestelsel Hoofpyn, duiseligheid, slaperigheid, bewing, rusteloosheid. afwykings Gastroïntestinale afwykings Naarheid, braking, hardlywigheid, droë mond, dors. Psigiatriese afwykings Slaaploosheid, angstigheid, slaperigheid, verwardheid, verandering van gemoedstoestand. Hartafwykings Tagikardie, ventrikulêre aritmie, prekordiale pyn, palpitasies, bradikardie, hipertensie. Skeletspierstelsel- en Spierswakheid. bindweefsel afwykings Nier- en urienstelsel Moeilike urinering en spasma van die nier- en galbuise afwykings Oogafwykings Sametrekking van die pupil van die oog. Vaatsiekte Posturale hipotensie, verhoogde druk in die skedel Algemene afwykings Koors, abnormale lae liggaamstemperatuur. Page 18 of 23

19 BEKENDE SIMPTOME VAN OORDOSERING EN BESONDERHEDE VAN DIE BEHANDELING DAARVAN Raadpleeg jou geneesheer indien meer as die aanbevole dosis geneem is, of neem die pasiënt dadelik na die naaste hospitaal. Vir addisionele nood-inligting, skakel jou naaste vergiftigingssentrum. Parasetamol Onmiddellike behandeling is noodsaaklik. In geval van oordosering raadpleeg dadelik ʼn dokter, of neem die persoon direk na die hospitaal. ʼn Vertraging in die aanvang van behandeling kan daartoe lei dat die teenmiddel te laat gegee word om doeltreffend te wees. Tekens van lewerskade word dikwels vertraag, dus kan die tydperk waarin doeltreffende behandeling toegedien kan word, dan al verstreke wees. Vatbaarheid vir parasetamoltoksisiteit is hoër onder pasiënte wat herhaaldelik hoë dosisse parasetamol (meer as 5-10 g/dag) vir ʼn paar dae geneem het, by chroniese alkoholisme, chroniese lewersiekte, VIGS, wanvoeding en met die gebruik van geneesmiddels wat hepatiese mikrosomale oksidase induseer, soos barbiturate, isoniasied, rifampisien, fenitoïen en karbamasepien. Simptome van parasetamoloordosering in die eerste 24 uur sluit in bleekheid, naarheid, braking, anoreksie en moontlike maagpyn. Ligte simptome in die eerste twee dae na akute vergiftiging weerspieël nie die moontlike erns van die oordosering nie. Lewerskade kan 12 tot 48 uur, of selfs langer, ná inname na vore tree, aanvanklik deur verhoging van die serumtransaminase- en melksuurdehidrogenase werking, verhoogde serumbilirubienkonsentrasie en verlenging van die protrombientyd. Lewerskade kan tot enkefalopatie, koma en dood lei. Page 19 of 23

20 Akute nierversaking met akute tubulêre nekrose kan ontwikkel selfs al is daar nie ernstige lewerskade nie. Abnormaliteite van glukosemetabolisme en metaboliese asidose kan voorkom. Hartaritmieë is aangemeld. Behandeling vir parasetamoloordosering: Alhoewel inligting beperk is, word dit aanbeveel dat maagspoeling (emese kan voldoende wees by kinders) op enige volwasse persoon wat 5-10 gram of meer parasetamol (of ʼn kind meer as 140 mg/kg) gedurende die vorige vier uur ingeneem het, uitgevoer moet word en dat ʼn enkeldosis van 50 g geaktiveerde houtskool deur die maagspoelbuis toegedien moet word. Inname van kleiner as hierdie hoeveelhede parasetamol kan behandeling noodsaak by pasiënte wat vir parasetamolvergiftiging vatbaar is (sien hierbo). By bedwelmde of komateuse pasiënte moet endotrageale intubering die maagspoeling voorafgaan om aspirasie te voorkom. N-asetielsisteïen moet so gou as moontlik, verkieslik binne agt uur van oordosering, aan alle gevalle waar oordosering vermoed word toegedien word, alhoewel behandeling vir tot 36 uur na inname steeds voordelig kan wees, veral as meer as 150 mg/kg parasetamol ingeneem is. ʼn Aanvanklike dosis van 150 mg/kg N-asetielsisteïen in 200 ml dekstrose-inspuiting intraveneus oor 15 minute gegee, gevolg deur ʼn infusie van 50 mg/kg in 500 ml dekstrose-inspuiting oor die volgende vier uur en dan 100 mg/kg in ml dekstrose-inspuiting oor die volgende sestien uur. Die volume intraveneuse vloeistof moet vir kinders aangepas word. Alhoewel die mondelike formulering nie die behandeling van keuse is nie, kan 140 mg/kg, opgelos in water, aanvanklik toegedien word, gevolg deur 70 mg/kg elke vier uur vir sewentien dosisse. Die plasmaparasetamolvlakke moet by alle gevalle waar oordosering vermoed word, elke vier uur na inname bepaal word. Vlakke wat voor vier uur bepaal word, tensy dit hoog is, kan misleidend wees. Pasiënte wat aan ʼn risiko vir lewerskade blootgestel is en dus voortgesette behandeling met Page 20 of 23

21 N-asetielsisteïen benodig, kan volgens hulle plasmaparasetamolvlakke uitgeken word. Die plasmaparasetamolvlak teenoor tyd sedert inname kan in die onderstaande nomogram aangeteken word. Bron: Goodman & Gilman s The Pharmacological Basis of Therapeutics, 11 th edition. Diegene met plasmaparasetamolvlakke bokant die normale behandelingslyn moet met N-asetielsisteïenbehandeling van 100 mg/kg IV oor sestien uur herhaaldelik voortgaan totdat herstel bereik is. Pasiënte met verhoogde vatbaarheid vir lewerskade, soos hierbo aangedui, moet aanhou met behandeling as konsentrasies bokant die hoë-risiko behandelingslyn is. Die protrombienindeks korreleer die beste met oorlewing. Moniteer alle pasiënte wat beduidende hoeveelhede ingeneem het vir ten minste ses-en-negentig uur. Pseudoefedrien Simptome van pseudoefedrien oordosis bestaan hoofsaaklik uit ligte angs, verhoogde hartkloptempo en/of ʼn geringe styging in bloeddruk. Simptome verskyn gewoonlik binne 4 tot 8 uur na inname. Page 21 of 23

22 Kodeïen Kodeïen oordosering kan aanleiding gee tot simptome wat insluit rusteloosheid, opgewondenheid, abnormale stadige en/of vlak asemhaling en lae bloeddruk met ineenstorting van die bloedsomloopstelsel en koma. Toevalle kan by kinders voorkom. Die spesifieke antagonis, naloksoonhidrochloried kan gebruik word om die erge asemhalingsonderdrukking teen te werk. IDENTIFIKASIE ʼn Plat, ronde, wit tablet met afgeplatte kante en "SINUMAX CO" gedruk op die een kant en ʼn breeklyn op die ander kant. AANBIEDING Sekuriteitsbottels met 20 tablette. BERGINGSINSTRUKSIES Bewaar teen of benede 25 C. Beskerm teen lig, vog en blootstelling aan lug. HOU BUITE BEREIK VAN KINDERS REGISTRASIENOMMER 29/5.8/0004 NAAM EN BESIGHEIDSADRES VAN DIE HOUER VAN DIE REGISTRASIESERTIFIKAAT JANSSEN PHARMACEUTICA (Pty) Ltd (Reg. nr. 1980/011122/07) Gebou 6, Country Club Estate, Woodlandsrylaan 21, Woodmead, 2191 Page 22 of 23

23 Tel: +27 (11) DATUM VAN PUBLIKASIE VAN HIERDIE VOUBILJET: Februarie 2015 Page 23 of 23

INDICATIONS: For the relief of mild to moderate pain and fever such as headaches, toothache and pain associated with colds and flu.

INDICATIONS: For the relief of mild to moderate pain and fever such as headaches, toothache and pain associated with colds and flu. SCHEDULING STATUS: S0 PROPRIETARY NAME: (AND DOSAGE FORM) PANADO EFFERVESCENT (TABLETS) COMPOSITION: Each tablet contains: 500 mg paracetamol. Sugar free. PHARMACOLOGICAL CLASSIFICATION: A 2.7 Antipyretic

More information

QA Amendment Sugar and layout 09/03/2007

QA Amendment Sugar and layout 09/03/2007 SCHEDULING STATUS: S0 QA Amendment PROPRIETARY NAME: (and dosage form) PANADO INFANT DROPS (Drops) COMPOSITION: Each 0,6 ml contains: Paracetamol Preservatives: Methylparaben Propylparaben 60 mg 0,085%

More information

SCHEDULING STATUS: S0 For pack sizes of 24 tablets or less. For pack sizes of more than 24 tablets

SCHEDULING STATUS: S0 For pack sizes of 24 tablets or less. For pack sizes of more than 24 tablets SCHEDULING STATUS: S0 For pack sizes of 24 tablets or less S1 For pack sizes of more than 24 tablets PROPRIETARY NAME: AND DOSAGE FORM PANADO MELTABS (Tablets) COMPOSITION: Each tablet contains 500 mg

More information

PROPOSED PACKAGE INSERT. Each tablet contains 37,5 mg tramadol hydrochloride and 325 mg paracetamol as the active ingredients.

PROPOSED PACKAGE INSERT. Each tablet contains 37,5 mg tramadol hydrochloride and 325 mg paracetamol as the active ingredients. PROPOSED PACKAGE INSERT SCHEDULING STATUS Schedule 5 PROPRIETARY NAME AND DOSAGE FORM TRAMACET Tablets COMPOSITION Each tablet contains 37,5 mg tramadol hydrochloride and 325 mg paracetamol as the active

More information

FOR ANIMAL USE ONLY. BERENIL R.T.U. Reg. No. G2702 (Act 36/1947) Namibia Reg. No. V00/17.4.2/638 NS0

FOR ANIMAL USE ONLY. BERENIL R.T.U. Reg. No. G2702 (Act 36/1947) Namibia Reg. No. V00/17.4.2/638 NS0 FOR ANIMAL USE ONLY BERENIL R.T.U. Reg. No. G2702 (Act 36/1947) Namibia Reg. No. V00/17.4.2/638 NS0 INDICATIONS Berenil R.T.U. cures and prevents Redwater in cattle and cures biliary fever in dogs and

More information

PRODUCT INFORMATION. (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate

PRODUCT INFORMATION. (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate NORGESIC Orphenadrine citrate and paracetamol PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Chemical name: CAS number: 4682-36-4 Chemical structure: Orphenadrine citrate (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine

More information

APPROVED PACKAGE INSERT FOR INGELVAC MYCOFLEX

APPROVED PACKAGE INSERT FOR INGELVAC MYCOFLEX APPROVED PACKAGE INSERT FOR INGELVAC MYCOFLEX Only for use by or under the supervision of persons registered in terms of or authorised in terms of section 23 (1) (c) of the Veterinary and Para-Veterinary

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET 1. PRODUCT NAME Sudomyl, Tablet, 60 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Pseudoephedrine Hydrochloride 60mg Excipient(s) with known effect For the full

More information

PRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets

PRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets PRODUCT INFORMATION SUDAFED Sinus 12 Hour Relief Tablets NAME OF THE MEDICINE Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 DESCRIPTION SUDAFED Sinus 12 Hour Relief prolonged-release tablets

More information

PARACOD Tablets (Paracetamol + Codeine phosphate)

PARACOD Tablets (Paracetamol + Codeine phosphate) Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s

More information

Dilaudid, a narcotic analgesic, is prescribed for the relief of moderate to severe pain such as that due to:

Dilaudid, a narcotic analgesic, is prescribed for the relief of moderate to severe pain such as that due to: DrugFAQs Dilaudid Generic name: Hydromorphone hydrochloride Brand names: Dilaudid Why is Dilaudid prescribed? Dilaudid, a narcotic analgesic, is prescribed for the relief of moderate to severe pain such

More information

*Gebaseer op die Nasionale Kanker Register Leeftyd risiko vir prostaatkanker 1:27. testikulêrekanker 1: peniskanker 1:1 114

*Gebaseer op die Nasionale Kanker Register Leeftyd risiko vir prostaatkanker 1:27. testikulêrekanker 1: peniskanker 1:1 114 *Gebaseer op die Nasionale Kanker Register 2010 Leeftyd risiko vir prostaatkanker 1:27 Leeftyd risiko vir testikulêrekanker Leeftyd risiko vir peniskanker 1:2 040 1:1 114 Prostaatkanker 1 uit 27 Suid-Afrikaanse

More information

KYNOBUFF IN CASE OF POISONING PLEASE PHONE / IN GEVAL VAN VERGIFTIGING SKAKEL l Netto Volume

KYNOBUFF IN CASE OF POISONING PLEASE PHONE / IN GEVAL VAN VERGIFTIGING SKAKEL l Netto Volume KYNOBUFF Reg. No.L4246, Act No./Wet Nr. 36 of/van 1947 A ph buffer for increasing the efficiency of ph sensitive agricultural remedies and improving the wetting and spreading properties of spray mixtures.

More information

Migraleve, Migraleve Pink and Migraleve Yellow Product Information

Migraleve, Migraleve Pink and Migraleve Yellow Product Information Migraleve, Migraleve Pink and Migraleve Yellow Product Information Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also

More information

PRODUCT INFORMATION Panadeine EXTRA

PRODUCT INFORMATION Panadeine EXTRA PRODUCT INFORMATION Panadeine EXTRA COMPOSITION Each caplet brand of capsule-shaped tablet contains: Paracetamol 500 mg Codeine phosphate 15 mg and Maize Starch Purified Talc Pregelatinised Maize Starch

More information

Package leaflet: Information for the user CODEINE PHOSPHATE TABLETS BP 15mg and 30mg (Codeine Phosphate)

Package leaflet: Information for the user CODEINE PHOSPHATE TABLETS BP 15mg and 30mg (Codeine Phosphate) Package leaflet: Information for the user CODEINE PHOSPHATE TABLETS BP 15mg and 30mg (Codeine Phosphate) Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol Hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol Hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Meptid 100 mg/ml Solution for Injection Meptazinol Hydrochloride Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet.

More information

PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets

PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets NAME OF THE MEDICINE Active Ingredients: Paracetamol and Codeine Phosphate Paracetamol: Molecular Formula: C 8 H

More information

PRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets

PRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets PRODUCT INFORMATION Sudafed* Sinus Day + Night Relief Tablets Product description Sudafed* Sinus Day + Night Relief tablets contain two separate formulations: day tablets and night tablets. Each Sudafed*

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. EPHEDRINE HCl STEROP 10mg/ml EPHEDRINE HCl STEROP 50mg/ml Solution for injection. Ephedrine Hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. EPHEDRINE HCl STEROP 10mg/ml EPHEDRINE HCl STEROP 50mg/ml Solution for injection. Ephedrine Hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER EPHEDRINE HCl STEROP 10mg/ml EPHEDRINE HCl STEROP 50mg/ml Solution for injection Ephedrine Hydrochloride Read all of this leaflet carefully before you start using

More information

Maxilief Effervescent Tablets

Maxilief Effervescent Tablets Package Leaflet: Information for the user Maxilief Effervescent Tablets Paracetamol Codeine Phosphate Hemihydrate Caffeine 500mg 8mg 30mg Read all of this leaflet carefully before you start taking this

More information

AVIOMARIN 50 mg tablets

AVIOMARIN 50 mg tablets PACKAGE LEAFLET: INFORMATION FOR THE USER AVIOMARIN 50 mg tablets DIMENHYDRINATE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines

More information

Panadeine Tablet, Caplets and Rapid Soluble tablets PRODUCT INFORMATION

Panadeine Tablet, Caplets and Rapid Soluble tablets PRODUCT INFORMATION Panadeine Tablet, Caplets and Rapid Soluble tablets PRODUCT INFORMATION DESCRIPTION Active Ingredients Paracetamol 500 mg Codeine Phosphate 8 mg Excipients Tablets - Starch - maize, talc - purified, stearic

More information

PRODUCT INFORMATION. Sudafed* Sinus + Allergy & Pain Relief Tablets

PRODUCT INFORMATION. Sudafed* Sinus + Allergy & Pain Relief Tablets PRODUCT INFORMATION Sudafed* Sinus + Allergy & Pain Relief Tablets Name of the Medicine Paracetamol CAS 2 Registry Number: 103-90-2 Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 Triprolidine

More information

PRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets

PRODUCT INFORMATION. Sudafed* Sinus Day + Night Relief Tablets PRODUCT INFORMATION Sudafed* Sinus Day + Night Relief Tablets Name of the Medicine Paracetamol CAS 2 Registry Number: 103-90-2 Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 Triprolidine

More information

Farmadol. Paracetamol 10 mg/ml INFUSION SOLUTION

Farmadol. Paracetamol 10 mg/ml INFUSION SOLUTION Farmadol Paracetamol 10 mg/ml INFUSION SOLUTION Composition Each ml contains: Paracetamol 10 mg Pharmacology Pharmacodynamic properties The precise mechanism of the analgesic and antipyretic properties

More information

NEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.

NEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face. 1. PRODUCT NAME ACUPAN 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains nefopam hydrochloride 30 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM

More information

Molecular formula: Molecular weight: C 8 H 9 NO 2 CAS Registry no.:

Molecular formula: Molecular weight: C 8 H 9 NO 2 CAS Registry no.: Parapane Paracetamol PRODUCT INFORMATION NAME OF THE MEDICINE Active ingredient: Chemical name: Paracetamol N-(4-hydroxyphenyl) Structural formula: Molecular formula: 151.20 Molecular weight: C 8 H 9 NO

More information

PHARMACY ACTION COLD & FLU DAY & NIGHT paracetamol, pseudoephedrine hydrochloride, chlorphenamine maleate

PHARMACY ACTION COLD & FLU DAY & NIGHT paracetamol, pseudoephedrine hydrochloride, chlorphenamine maleate CONSUMER MEDICINE INFORMATION PHARMACY ACTION COLD & FLU DAY & NIGHT paracetamol, pseudoephedrine hydrochloride, chlorphenamine maleate What is in this leaflet This leaflet answers some common questions

More information

APOHEALTH Cold & Flu Relief Day/Night Tablets

APOHEALTH Cold & Flu Relief Day/Night Tablets Day/Night Tablets Contains the active ingredients Paracetamol, Pseudoephedrine hydrochloride, Codeine phosphate and Chlorpheniramine maleate Consumer Medicine Information For a copy of a large print leaflet,

More information

Package leaflet: Information for the user Tylex 30 mg / 500 mg Effervescent Tablets. Codeine phosphate hemihydrate, Paracetamol

Package leaflet: Information for the user Tylex 30 mg / 500 mg Effervescent Tablets. Codeine phosphate hemihydrate, Paracetamol Package leaflet: Information for the user Tylex 30 mg / 500 mg Effervescent Tablets Codeine phosphate hemihydrate, Paracetamol Read all of this leaflet carefully before you start taking this medicine because

More information

Active Ingredients: Chlorpheniramine maleate 1,25 mg and phenylephrine hydrochloride

Active Ingredients: Chlorpheniramine maleate 1,25 mg and phenylephrine hydrochloride SCHEDULING STATUS S2 PROPRIETARY NAME AND DOSAGE FORM DEMAZIN Syrup COMPOSITION Each 5 ml contains: Active Ingredients: Chlorpheniramine maleate 1,25 mg and phenylephrine hydrochloride 2,5 mg. Inactive

More information

PRODUCT INFORMATION. Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets

PRODUCT INFORMATION. Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets PRODUCT INFORMATION Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets Product description Sudafed* Sinus + Anti-inflammatory Pain Relief caplets contain pseudoephedrine hydrochloride 30 mg and ibuprofen

More information

Package leaflet: Information for the user. Co-Codamol 30mg/500mg Capsules (Codeine Phosphate Hemihydrate and Paracetamol)

Package leaflet: Information for the user. Co-Codamol 30mg/500mg Capsules (Codeine Phosphate Hemihydrate and Paracetamol) Package leaflet: Information for the user Co-Codamol 30mg/500mg Capsules (Codeine Phosphate Hemihydrate and Paracetamol) Read all of this leaflet carefully before you start taking this medicine because

More information

PRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.

PRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes. PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine

More information

PRODUCT INFORMATION. Codral* Original Cold & Flu Tablets

PRODUCT INFORMATION. Codral* Original Cold & Flu Tablets PRODUCT INFORMATION Codral* Original Cold & Flu Tablets Product description Codral* Original Cold & Flu tablets contain paracetamol 500 mg, pseudoephedrine hydrochloride 30 mg and codeine phosphate 6 mg.

More information

Package leaflet: Information for the user. Morfin Abcur 10 mg/ml, solution for injection. morphine hydrochloride

Package leaflet: Information for the user. Morfin Abcur 10 mg/ml, solution for injection. morphine hydrochloride Package leaflet: Information for the user Morfin Abcur 10 mg/ml, solution for injection morphine hydrochloride Read all of this leaflet carefully before you start using this medicine because it contains

More information

[Type text] Page 1 of 15

[Type text] Page 1 of 15 PACKAGE INSERT SCHEDULING STATUS Schedule 6 PROPRIETARY NAME (and dosage form) SUFENTA 2 ml injection SUFENTA 10 ml injection COMPOSITION Each ml contains sufentanil citrate 0,0075 mg equivalent to 0,005

More information

PRODUCT INFORMATION LEAFLET

PRODUCT INFORMATION LEAFLET PRODUCT INFORMATION LEAFLET 1. Product Name Brand Name: Crocin Cold & Flu Max Generic Name: Paracetamol, Caffeine and Phenylephrine Hydrochloride Tablets 2. Qualitative & Quantitative Composition Each

More information

ACTIVE INGREDIENT / AKTIEWE BESTANDDEEL: Brodifacoum (Anticoagulant) /Brodifakoum (Bloedstolweermiddel)..0,75 g / 500 m ; 1 Litre

ACTIVE INGREDIENT / AKTIEWE BESTANDDEEL: Brodifacoum (Anticoagulant) /Brodifakoum (Bloedstolweermiddel)..0,75 g / 500 m ; 1 Litre MAIN PANEL RODEX LIQUID BAIT Reg. No./Nr.: L9289 Act /Wet 36 /1947 A highly active anticoagulant liquid bait concentrate for the control of the Norway Rat (Rattus norwegicus), Roof Rat (Rattus rattus),

More information

Package leaflet: Information for the user NON DROWSY SUDAFED. DECONGESTANT 60 mg FILM-COATED TABLETS Pseudoephedrine hydrochloride

Package leaflet: Information for the user NON DROWSY SUDAFED. DECONGESTANT 60 mg FILM-COATED TABLETS Pseudoephedrine hydrochloride Package leaflet: Information for the user NON DROWSY SUDAFED DECONGESTANT 60 mg FILM-COATED TABLETS Pseudoephedrine hydrochloride Read all of this leaflet carefully before you start using this medicine

More information

PANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other.

PANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other. Product description PANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other. Ingredients Active Ingredients: Paracetamol

More information

VERTE-X-PLODE Reg. No. B 3602 Act/Wet No. 36 of/van 1947

VERTE-X-PLODE Reg. No. B 3602 Act/Wet No. 36 of/van 1947 VERTE-X-PLODE Reg. No. B 3602 Act/Wet No. 36 of/van 1947 ACTIVE INGREDIENTS / AKTIEWE BESTANDDELE: K.51.3 g/kg P.40.7 g/kg Mo..41 mg/kg B.360 mg/kg Chelated / Cheleerd Fe.3942 mg/kg Mn.1440 mg/kg Zn..990

More information

Codral Original Day & Night Cold & Flu Tablets Paracetamol, Pseudoephedrine hydrochloride, Codeine phosphate, Triprolidine hydrochloride

Codral Original Day & Night Cold & Flu Tablets Paracetamol, Pseudoephedrine hydrochloride, Codeine phosphate, Triprolidine hydrochloride Codral Original Day & Night Cold & Flu Tablets Paracetamol, Pseudoephedrine hydrochloride, Codeine phosphate, Triprolidine hydrochloride Consumer Medicine Information What is in this leaflet This leaflet

More information

Read all of this leaflet carefully before you start taking this medicine. If you have further questions, please ask your doctor or pharmacist.

Read all of this leaflet carefully before you start taking this medicine. If you have further questions, please ask your doctor or pharmacist. INFORMATION FOR THE PATIENT ABOUT OxyContin Prolonged Release Tablets Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again. If you

More information

CCDS May 2008 Page 1 of 26

CCDS May 2008 Page 1 of 26 PACKAGE INSERT SCHEDULING STATUS Schedule 6 PROPRIETARY NAME (and dosage form) SUFENTA FORTE injection COMPOSITION Each ml contains sufentanil citrate 0,075 mg equivalent to 0,050 mg of sufentanil base

More information

Codral Original Day & Night Cold & Flu Tablets

Codral Original Day & Night Cold & Flu Tablets & Flu Tablets Paracetamol, Pseudoephedrine hydrochloride, Codeine phosphate, Triprolidine hydrochloride Consumer Medicine Information What is in this leaflet This leaflet answers some common questions

More information

SANDOMIGRAN (pizotifen malate)

SANDOMIGRAN (pizotifen malate) SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.

More information

PACKAGE INSERT TEMPLATE FOR PARACETAMOL SUPPOSITORIES

PACKAGE INSERT TEMPLATE FOR PARACETAMOL SUPPOSITORIES PACKAGE INSERT TEMPLATE FOR PARACETAMOL SUPPOSITORIES Brand or Product Name [Product name] Suppositories mg Name and Strength of Active Substance(s) Eg Paracetamol 500mg Paracetamol 250mg Paracetamol 125mg

More information

PHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker

PHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker PACKAGE INSERT Pr PHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker ACTIONS AND CLINICAL PHARMACOLOGY Phentolamine produces an alpha-adrenergic

More information

Your Pharmacy Paracetamol Plus, capsule shaped tablets (caplets)

Your Pharmacy Paracetamol Plus, capsule shaped tablets (caplets) New Zealand Data Sheet Product Description Your Pharmacy Plus, capsule shaped tablets (caplets) 500 mg per tablet & Codeine Phosphate 10 mg per tablet Blister packs of white, capsule-shaped tablets Composition

More information

SPASMEX FORTE 5mg tablets

SPASMEX FORTE 5mg tablets PACKAGE LEAFLET: INFORMATION FOR THE USER SPASMEX FORTE 5mg tablets TROSPIUM This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines

More information

F U N G I N E X. Active Ingredient / Aktiewe Bestanddeel. Triforine g/l...triforien

F U N G I N E X. Active Ingredient / Aktiewe Bestanddeel. Triforine g/l...triforien F U N G I N E X REG. NO. L 2469 / N-AR 0131 ACT NO 36 of 1947 W 130281 AN EMULSIFIABLE CONCENTRATE 'N EMULGEERBARE KONSENTRAAT SYSTEMIC FUNGICIDE FOR THE SISTEMIESE SWAMDODER VIR DIE CONTROL OF POWDERY

More information

MUSIEK - VOKAAL. 17 Augustus 20 Augustus Voorsitter: Lorraine Kirk

MUSIEK - VOKAAL. 17 Augustus 20 Augustus Voorsitter: Lorraine Kirk MUSIEK - VOKAAL 17 Augustus 20 Augustus 2015 Voorsitter: Lorraine Kirk - 082 689 2707 lorrainekirk58@gmail.com Die algemene reëls moet saam met die spesifieke reëls gelees word INSKRYWINGSFOOIE Solo R

More information

A water-soluble foliar feed with a wide range of nutrients for plants. n Wateroplosbare blaarvoeding met n wye reeks voedingselemente vir plante.

A water-soluble foliar feed with a wide range of nutrients for plants. n Wateroplosbare blaarvoeding met n wye reeks voedingselemente vir plante. FERTILIZER GROUP / MISSTOF GROEP II Reg. No. K 7652 Act/Wet 36 of/van 1947 1: 08/02/07 Oct 2013 Feed-P 2.1.2 (44) A water-soluble foliar feed with a wide range of nutrients for plants. n Wateroplosbare

More information

Submitted: 19 February 2015 Reference: RA/2016/02/031cp Amendment type: Response to DHCP letter and compliant response to CCC dated 02 December 2014

Submitted: 19 February 2015 Reference: RA/2016/02/031cp Amendment type: Response to DHCP letter and compliant response to CCC dated 02 December 2014 PACKAGE INSERT SCHEDULING STATUS Schedule 4 PROPRIETARY NAME AND DOSAGE FORM MOTILIUM 1 mg/ml suspension COMPOSITION Each ml contains 1 mg domperidone, with 0,18 % m/v methylparaben and 0,02 % m/v propylparaben

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate)

PACKAGE LEAFLET: INFORMATION FOR THE USER. DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate) PACKAGE LEAFLET: INFORMATION FOR THE USER DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate) Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need

More information

Package leaflet: Information for the patient. Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate

Package leaflet: Information for the patient. Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate Package leaflet: Information for the patient Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate Read all of this leaflet carefully before you start using this medicine because

More information

TRIPROLIDINE. Please read this leaflet and the packaging of the medicine you purchased, carefully before you start using triprolidine.

TRIPROLIDINE. Please read this leaflet and the packaging of the medicine you purchased, carefully before you start using triprolidine. TRIPROLIDINE New Zealand Consumer Medicine Information What is in this leaflet The medicine you have purchased contains triprolidine. This leaflet is intended to provide information on the active ingredient

More information

NEOPYBUTHRIN. REG. NO. L4582 Act No. 36 of 1947 REG. NR. L4582 Wet Nr. 36 van 1947 Namibian Reg. No. N-AR 0592 Nambiese Reg. Nr.

NEOPYBUTHRIN. REG. NO. L4582 Act No. 36 of 1947 REG. NR. L4582 Wet Nr. 36 van 1947 Namibian Reg. No. N-AR 0592 Nambiese Reg. Nr. NEOPYBUTHRIN REG. NO. L4582 Act No. 36 of 1947 REG. NR. L4582 Wet Nr. 36 van 1947 Namibian Reg. No. N-AR 0592 Nambiese Reg. Nr. N-AR 0592 MISTING AND FOGGING SOLUTION FOR THE CONTROL OF COCKROACHES, HOUSE

More information

Chemists Own Strong Pain Extra Paracetamol and Codeine Phosphate

Chemists Own Strong Pain Extra Paracetamol and Codeine Phosphate Chemists Own Strong Pain Extra Paracetamol and Codeine Phosphate Consumer Medicine Information(CMI) Please read this information before you start taking this medicine. What is in this CMI? This CMI answers

More information

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Paracetamol 80mg Suppositories 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each suppository contains 80mg Paracetamol For a full list of

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol

PACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol PACKAGE LEAFLET: INFORMATION FOR THE USER Meptid 100 mg/ml Solution for Injection Meptazinol Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need

More information

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.

Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine

More information

LEAFLET: INFORMATION FOR THE USER. Freshalgin 500th mg tablets Metamizole sodium (M etamizol sodium)

LEAFLET: INFORMATION FOR THE USER. Freshalgin 500th mg tablets Metamizole sodium (M etamizol sodium) LEAFLET: INFORMATION FOR THE USER Freshalgin 500th mg tablets Metamizole sodium (M etamizol sodium) Read this leaflet carefully before you start taking this medicine. This medicine is available without

More information

PACKAGE INSERT. Each JURNISTA 4 mg extended-release tablet contains 4,36 mg and delivers 4 mg hydromorphone

PACKAGE INSERT. Each JURNISTA 4 mg extended-release tablet contains 4,36 mg and delivers 4 mg hydromorphone PACKAGE INSERT SCHEDULING STATUS Schedule 6 PROPRIETARY NAME AND DOSAGE FORM JURNISTA JURNISTA 4 mg extended-release tablets 8 mg extended-release tablets JURNISTA 16 mg extended-release tablets Contains

More information

Each 5ml of Sinarest LP New Syrup contains: Phenylephrine

Each 5ml of Sinarest LP New Syrup contains: Phenylephrine Composition: Each 5ml of Sinarest LP New Syrup contains: Paracetamol Phenylephrine Levocetrizine 250mg 5mg 1.25mg Pharmacokinetic properties: Paracetamol is readily absorbed from the gastrointestinal tract

More information

PACKAGE LEAFLET Page 1 of 6

PACKAGE LEAFLET Page 1 of 6 PACKAGE LEAFLET Page 1 of 6 Package leaflet: Information for the patient Pindolol 5 mg Tablets pindolol Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

PANADOL SINUS DAY & NIGHT TABLETS PRODUCT INFORMATION

PANADOL SINUS DAY & NIGHT TABLETS PRODUCT INFORMATION Product description PANADOL SINUS DAY tablet is a white, film-coated capsule-shaped tablet with flat edges, front and back faces marked with DAY. PANADOL SINUS NIGHT tablet is a white, film-coated round

More information

Lactose monohydrate, maize starch, talc and magnesium stearate. The capsule

Lactose monohydrate, maize starch, talc and magnesium stearate. The capsule SCHEDULING STATUS Schedule 2 PROPRIETARY NAME AND DOSAGE FORM IMODIUM CAPS capsules COMPOSITION. The other ingredients are: Lactose monohydrate, maize starch, talc and magnesium stearate. The capsule itself

More information

This leaflet answers some common questions about Momex SR Tablets.

This leaflet answers some common questions about Momex SR Tablets. Momex SR Modified (Sustained) Release Tablets [Morphine sulphate] CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about Momex SR Tablets. It does not contain

More information

PRODEINE paracetamol and codeine phosphate hemihydrate

PRODEINE paracetamol and codeine phosphate hemihydrate PRODEINE paracetamol and codeine phosphate hemihydrate Consumer Medicine Information (CMI) What is in this leaflet This leaflet answers some common questions about Prodeine. It does not, however, contain

More information

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1. Name of Medicinal Product Co-Codamol 8/500 mg Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Paracetamol 500.0 mg Codeine Phosphate 8.0 mg For excipients, see section 6.1 3 PHARMACEUTICAL FORM

More information

Package Leaflet: Information for the user

Package Leaflet: Information for the user Boots Pharmaceuticals logo Paracetamol & Codeine Tablets (Codeine phosphate and Paracetamol) Package Leaflet: Information for the user Important things you should know about Boots Paracetamol & Codeine

More information

1. What Solpadol is and what it is used for

1. What Solpadol is and what it is used for PATIENT INFORMATION LEAFLET SOLPADOL 30mg/500mg CAPLETS Codeine Phosphate and Paracetamol Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read

More information

DATA SHEET. Paracetamol (BP) 500 mg and Phenylephrine Hydrochloride (BP) 5 mg

DATA SHEET. Paracetamol (BP) 500 mg and Phenylephrine Hydrochloride (BP) 5 mg COLDREX PE PHENYLEPHRINE SINUS COLDREX PE PHENYLEPHRINE CONGESTION CLEAR PANADOL SINUS PAIN & CONGESTION RELIEF PANADOL COLD & FLU MAX + DECONGESTANT DATA SHEET Paracetamol (BP) 500 mg and Phenylephrine

More information

PATIENT INFORMATION LEAFLET CARVETREND RANGE

PATIENT INFORMATION LEAFLET CARVETREND RANGE SCHEDULING STATUS: S3 PATIENT INFORMATION LEAFLET PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: CARVETREND 6,25 mg tablet. CARVETREND 12,5 mg tablet. CARVETREND 25 mg tablet. Please read this leaflet

More information

Rift Valley fever is a fever-causing viral disease that affects livestock and humans in Africa. It is most common during years of heavy rainfall.

Rift Valley fever is a fever-causing viral disease that affects livestock and humans in Africa. It is most common during years of heavy rainfall. Slenkdalkoors Slenkdalkoors is n erge insekgedraagde virussiekte wat hoefdiere soos skape, bokke en beeste aantas. Dit hou ook n ernstige gesondheidsgevaar vir die mens in. Diere word aanvanklik besmet

More information

PATIENT INFORMATION LEAFLET

PATIENT INFORMATION LEAFLET PPM Code: E1981 PATIENT INFORMATION LEAFLET SCHEDULING STATUS: S2 PROPRIETARY NAME DOSAGE FORM: film coated tablets Read all of this leaflet carefully because it contains important information for you.

More information

SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS

SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive

More information

PRODUCT INFORMATION ACTACODE

PRODUCT INFORMATION ACTACODE PRODUCT INFORMATION ACTACODE NAME OF THE MEDICINE Actacode codeine linctus contains codeine phosphate 5 mg/ml. Codeine phosphate is (5R,6S)-7,8-didehydro-4,5-epoxy-3-methoxy-N-methylmorphinan-6-ol dihydrogen

More information

Consumer Medicine Information

Consumer Medicine Information Consumer Medicine Information Trade Name: ZOLPIDEM-DP Active Ingredient: Zolpidem tartrate Warning: Zolpidem may be associated with unusual and potentially dangerous behaviours whilst apparently asleep.

More information

European PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam

European PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages

More information

Composition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:

Composition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties: Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved

More information

Before you use DEMAZIN Day & Night Cold & Flu. What is in this leaflet. What DEMAZIN Day & Night Cold & Flu is used for. Consumer Medicine Information

Before you use DEMAZIN Day & Night Cold & Flu. What is in this leaflet. What DEMAZIN Day & Night Cold & Flu is used for. Consumer Medicine Information Tablets Day tablets: Pseudoephedrine hydrochloride, paracetamol and codeine phosphate; Night tablets: Pseudoephedrine hydrochloride, paracetamol and chlorpheniramine maleate Consumer Medicine Information

More information

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII)

MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental use by a child is a medical emergency

More information

PRODUCT INFORMATION. Active ingredients Chemical structure CAS Registry Number. Paracetamol

PRODUCT INFORMATION. Active ingredients Chemical structure CAS Registry Number. Paracetamol PRODUCT INFORMATION PANADOL SINUS PAIN & CONGESTION RELIEF CAPLETS PANADOL COLD & FLU PLUS DECONGESTANT CAPLETS NAME OF THE MEDICINE Active ingredients Chemical structure CAS Registry Number Paracetamol

More information

BOND. Reg. No./Reg. Nr. L6756, Act No. 36 of 1947/Wet Nr. 36 van 1947

BOND. Reg. No./Reg. Nr. L6756, Act No. 36 of 1947/Wet Nr. 36 van 1947 Sales Panel For further information see attached pamphlet Vir verdere inligting sien aangehegte pamflet Reg. No./Reg. Nr. L6756, Act No. 36 of 1947/Wet Nr. 36 van 1947 CONTAINS A STICKER AND A NON-IONIC

More information

PRESCRIBING INFORMATION WITH CONSUMER INFORMATION MYDRIACYL. tropicamide ophthalmic solution, USP. 0.5% and 1% w/v.

PRESCRIBING INFORMATION WITH CONSUMER INFORMATION MYDRIACYL. tropicamide ophthalmic solution, USP. 0.5% and 1% w/v. PRESCRIBING INFORMATION WITH CONSUMER INFORMATION Pr MYDRIACYL tropicamide ophthalmic solution, USP 0.5% and 1% w/v Anticholinergic Alcon Canada Inc. 2665 Meadowpine Blvd. Mississauga, ON L5N 8C7 www.alcon.ca

More information

RE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act

RE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act 22 January 2019 RE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act Dear Healthcare Professional, This notification

More information

Summary of Product Characteristics

Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Maxilief Effervescent Tablets Paracetamol 500mg Codeine Phosphate Hemihydrate 8mg Caffeine 30mg Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR: Core Safety Profile Active substance: Clotiazepam Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg P-RMS: BE/H/PSUR/0002/002 Date of FAR: 16.06.2011 4.3 Contraindications is contraindicated

More information

Hoe kan ek my maatjie wat kanker het help?

Hoe kan ek my maatjie wat kanker het help? Hoe kan ek my maatjie wat kanker het help? Wat is kanker? Kanker kan beskryf word as normale en gesonde selle in jou liggaam wat verander het in ongesonde kankerselle. Daar is baie redes vir hierdie veranderinge

More information

Shaded areas=not MARKETED 24/2/09

Shaded areas=not MARKETED 24/2/09 PACKAGE INSERT SCHEDULING STATUS Schedule 6 PROPRIETARY NAME AND DOSAGE FORM RAPIFEN 2 ml IV injection RAPIFEN 10 ml IV injection COMPOSITION Each ml contains alfentanil hydrochloride 0,544 mg (equivalent

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. MEPHENON 10mg/1ml, solution for injection MEPHENON 5mg, tablets. Methadone hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. MEPHENON 10mg/1ml, solution for injection MEPHENON 5mg, tablets. Methadone hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER MEPHENON 10mg/1ml, solution for injection MEPHENON 5mg, tablets Methadone hydrochloride Read all of this leaflet carefully before you start using this medicine

More information

DEPRESSIE101. panic attacks - inside the brain TALKING about anxiety attacks. hanteer angstigheid beter snellers vir 'n paniekaanval

DEPRESSIE101. panic attacks - inside the brain TALKING about anxiety attacks. hanteer angstigheid beter snellers vir 'n paniekaanval 9 A P R I L 2 0 1 8 U I T G A W E 2 5 DEPRESSIE101 panic attacks - inside the brain TALKING about anxiety attacks hanteer angstigheid beter snellers vir 'n paniekaanval PANIC ATTACKS: INSIDE THE BRAIN

More information

MEDICATION GUIDE Oxycodone Hydrochloride (ox-ee-co-dohn) (CII) Oral Solution, USP

MEDICATION GUIDE Oxycodone Hydrochloride (ox-ee-co-dohn) (CII) Oral Solution, USP MEDICATION GUIDE Oxycodone Hydrochloride (ox-ee-co-dohn) (CII) Oral Solution, USP IMPORTANT: Keep oxycodone hydrochloride oral solution in a safe place away from children. Accidental use by a child is

More information

APO-Paracetamol/Codeine 500/30 Contains the active ingredients, paracetamol and codeine phosphate

APO-Paracetamol/Codeine 500/30 Contains the active ingredients, paracetamol and codeine phosphate APO-Paracetamol/Codeine 500/30 Contains the active ingredients, paracetamol and codeine phosphate Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet

More information

Page 1 of 31 SCHEDULING STATUS PROPRIETARY NAMES AND DOSAGE FORM. OxyContin 5 mg Prolonged Release Tablets. OxyContin 10 mg Prolonged Release Tablets

Page 1 of 31 SCHEDULING STATUS PROPRIETARY NAMES AND DOSAGE FORM. OxyContin 5 mg Prolonged Release Tablets. OxyContin 10 mg Prolonged Release Tablets SCHEDULING STATUS S6 PROPRIETARY NAMES AND DOSAGE FORM OxyContin 5 mg Prolonged Release Tablets OxyContin 10 mg Prolonged Release Tablets OxyContin 20 mg Prolonged Release Tablets OxyContin 40 mg Prolonged

More information